Immunovia

Jeff Borcherding, CEO of Immunovia, comments:

“I want to extend a sincere thank you to all investors who chose to exercise their warrants of series TO 3. Your continued trust and support are deeply appreciated. This funding is an important step as we prepare for the commercial launch of our pancreatic cancer test — a milestone that brings us closer to delivering critical innovation to patients and healthcare providers”.

The exercise period for the Warrant Programme took place during the period 1 – 15 April 2025. One (1) warrant series TO 3 entitled the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.24 per share. A total of 44,174,217 warrants were exercised, corresponding to approximately 71.0 percent of the Warrant Programme, for the subscription of a total of 44,174,217 shares. Through the exercised warrants, Immunovia will thus receive a total of approximately 10.6 MSEK before issue costs.

Through the warrant exercise, the number of shares in Immunovia increases by 44,174,217 shares, from a total of 261,908,863 shares to 306 083 080 shares. The share capital increases by SEK 1,325,226.51 to SEK 9,182,492.40. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 14.4 percent based on the number of shares in Immunovia after the exercise of warrants.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into shares within approximately two (2) weeks.

Advisers
Vator Securities AB acts as financial adviser and Setterwalls Advokatbyrå AB as legal adviser to Immunovia in connection with the exercise of the Warrant Programme. Vator Securities AB also acts as the issuing agent.